Nathan L. Mata
CIK 2013987 · Chief Scientific Officer · last filed 2026-05-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
BLTE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN DIEGO, CA 92130
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BLTE | Chief Scientific Officer | 0 | $151.85 | $0 | -$2.52M | 17 | 2026-05-08 |
Recent Filings · Page 2 of 3
25 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-04-23 | BLTE | Sell (S)10b5-1 Plan adopted Dec 10, 2025 |
−1,000 | -$170.4K | EDGAR |
| 2026-04-22 | BLTE | Sell (S)10b5-1 Plan adopted Dec 10, 2025 |
−1,000 | -$166.0K | EDGAR |
| 2026-04-21 | BLTE | Sell (S)10b5-1 Plan adopted Dec 10, 2025 |
−1,000 | -$163.6K | EDGAR |
| 2026-04-20 | BLTE | Sell (S)10b5-1 Plan adopted Dec 10, 2025 |
−1,000 | -$161.6K | EDGAR |
| 2026-04-20 | BLTE | Sell (S)10b5-1 Plan adopted Dec 10, 2025 |
−1,000 | -$160.4K | EDGAR |
| 2026-04-16 | BLTE | Sell (S)10b5-1 Plan adopted Dec 10, 2025 |
−1,000 | -$168.3K | EDGAR |
| 2026-04-15 | Belite Bio, Inc. | Notice (144) Officer · Planned Apr 15, 2026 · 10b5-1 plan No sale on file |
−16,666 | -$2.87M | EDGAR |
| 2026-04-02 | BLTE | Grant (A) | — | $0 | EDGAR |
| 2025-08-21 | Belite Bio, Inc. | Notice (144) Officer · Planned Aug 21, 2025 · 10b5-1 plan No sale on file |
−30,000 | -$1.90M | EDGAR |
| 2025-03-19 | Belite Bio, Inc | Notice (144) Affiliate · Planned Mar 19, 2025 No sale on file |
−30,166 | -$2.05M | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).
Sales Reported Only on Form 144
6 sales · $4.49M| Sold | Symbol | Shares | Proceeds | Avg Price | Listed On |
|---|---|---|---|---|---|
| 2024-09-10 | Belite Bio, Inc | 5,337 | $254.5K | $47.68 | 2024-11-19 |
| 2024-09-06 | Belite Bio, Inc | 24,663 | $1.17M | $47.45 | 2024-11-19 |
| 2024-07-07 | Belite Bio, Inc | 30,000 | $1.44M | $48.07 | 2024-08-16 |
| 2024-05-28 | Belite Bio, Inc | 15,000 | $678.6K | $45.24 | 2024-08-16 |
| 2024-03-28 | Belite Bio, Inc | 15,000 | $678.6K | $45.24 | 2024-06-04 |
| 2024-03-25 | Belite Bio, Inc. | 6,000 | $261.1K | $43.52 | 2024-05-17 |